Diet/Growth Factor Mechanisms of Gut Adaptation

Key facts

Sponsor

Emory University

Principal Investigator

Thomas R Ziegler, MD

Emory University

Intervention

recombinant human growth hormone(drug)

Enrollment

27 enrolled

Eligibility

18-80 years · All sexes

Timeline

1996 – 2006

Study locations (1)

• Emory University School of Medicine, Atlanta, Georgia, United States

Collaborators

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Short bowel syndrome

Additional recruiting or active studies for the same condition.

• RECRUITINGNCT07319832
  A Study of Teduglutide in Chinese Children and Teenagers With Short Bowel Syndrome
  Takeda
• RECRUITINGPHASE3NCT07197944
  Efficacy And Safety Evaluation of Glepaglutide in Treatment of SBS
  Zealand Pharma
• ENROLLING BY INVITATIONPHASE3NCT07228403
  Efficacy and Safety Evaluation of Glepaglutide in Treatment of Short Bowel Syndrome
  Zealand Pharma
• RECRUITINGPHASE3NCT06973304
  A Study of Teduglutide in Chinese Adults With Short Bowel Syndrome
  Takeda
• RECRUITINGPHASE2NCT06904872
  Safety and Efficacy of Crofelemer in Adult Patients With Short Bowel Syndrome and Intestinal Failure (SBS-IF) Without Colon-in-continuity (CIC)
  Napo Therapeutics, S.p.A.
• RECRUITINGNANCT06877923
  Elemental 028 Extra Case Studies
  Nutricia UK Ltd
• RECRUITINGEARLY PHASE1NCT06326645
  Open-Label Pilot Study With Crofelemer in Patients With Short Bowel Syndrome
  Lindsey Russell, MD
• RECRUITINGNCT06771505
  SBS DISK- Creation of a Quality of Life Tool for Short Bowel Patients Compared With a Validated Quality of Life Questionnaire (SBS QoL)
  Hospices Civils de Lyon

See all trials for Short bowel syndrome →